Expression of osteoprotegerin and receptor activator for the nuclear factor‐κB ligand in XACB/LV‐bFGF/MSCs transplantation for repair of rabbit femoral head defect necrosis

2018 ◽  
Vol 120 (2) ◽  
pp. 1427-1434 ◽  
Author(s):  
Wuxun Peng ◽  
Jian Zhang ◽  
Fei Zhang ◽  
Yin Zhao ◽  
Wentao Dong
Keyword(s):  
Femoral Head ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Receptor Activator

scholarly journals Receptor activator of nuclear factor-κB ligand and osteoprotegerin

Cancer ◽  
2001 ◽  
Vol 92 (3) ◽  
pp. 460-470 ◽  
Author(s):  
Lorenz C. Hofbauer ◽  
Andreas Neubauer ◽  
Armin E. Heufelder
Keyword(s):  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Receptor Activator

Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor κB ligand/osteoprotegerin ratio

Bone ◽  
2008 ◽  
Vol 42 (3) ◽  
pp. 535-546 ◽  
Author(s):  
Dutmanee Seriwatanachai ◽  
Kanogwun Thongchote ◽  
Narattaphol Charoenphandhu ◽  
Jantarima Pandaranandaka ◽  
Kukiat Tudpor ◽  
...  
Keyword(s):  
Bone Turnover ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Receptor Activator

scholarly journals Receptor Activator of Nuclear Factor κB Ligand (RANKL)/Osteoprotegerin (OPG) Ratio Is Increased in Severe Osteolysis

2003 ◽  
Vol 163 (5) ◽  
pp. 2021-2031 ◽  
Author(s):  
Eva Grimaud ◽  
Luc Soubigou ◽  
Séverine Couillaud ◽  
Patrick Coipeau ◽  
Anne Moreau ◽  
...  
Keyword(s):  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Receptor Activator

Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis

2015 ◽  
Vol 86 (12) ◽  
pp. 1396-1404 ◽  
Author(s):  
Umut Balli ◽  
Ahmet Aydogdu ◽  
Figen Ongoz Dede ◽  
Cigdem Coskun Turer ◽  
Berrak Guven
Keyword(s):  
Gingival Crevicular Fluid ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Receptor Activator ◽  
Crevicular Fluid ◽  
Fluid Levels

Total Flavonoids of Bidens pilosa Ameliorates Bone Destruction in Collagen-Induced Arthritis

Planta Medica ◽  
2021 ◽  
Author(s):  
Mengqin Hong ◽  
Xingyu Fan ◽  
Shengxiang Liang ◽  
Wang Xiang ◽  
Liting Chen ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Proinflammatory Cytokines ◽  
Bone Destruction ◽  
Nuclear Factor Κb ◽  
Total Flavonoids ◽  
Nuclear Factor ◽  
Collagen Induced Arthritis ◽  
Bidens Pilosa ◽  
X Ray ◽  
Receptor Activator

AbstractRheumatoid arthritis is a chronic autoimmune disease characterized by the infiltration of synovial inflammatory cells and progressive joint destruction. Total flavonoids of Bidens pilosa have been used against inflammation in rheumatoid arthritis, but its role in bone destruction remains to be explored. The aim of this paper was to study whether total flavonoids of B. pilosa relieve the severity of collagen-induced arthritis in rats, particularly whether it regulates the production of proinflammatory cytokines and the receptor activator of nuclear factor-κB/receptor activator of nuclear factor-κB ligand/osteoprotegerin signaling pathway. In this research, a collagen-induced disease model was induced in adult rats by subcutaneous injection of collagen II. Total flavonoids of B. pilosa at different doses (40, 80, and 160 mg/kg/d) were administered intragastrically, while methotrexate (1 mg/kg/w) was injected intraperitoneally as a positive control. Paw swelling, arthritis score, and body weight were assessed and evaluated. The severity of joint damage was determined using X-ray and confirmed by histopathology. The expression levels of receptor activator of nuclear factor-κB ligand, osteoprotegerin, IL-1β, IL-17, and TNF in the serum and tissue were assayed using ELISA and immunohistochemistry. We found that total flavonoids of B. pilosa attenuated collagen-induced arthritis at the macroscopic level, and total flavonoids of B. pilosa-treated rats showed reduced paw swelling, arthritis scores, and X-ray appearance of collagen-induced arthritis in addition to improved histopathological results. These findings were consistent with reduced serum and tissue receptor activator of nuclear factor-κB ligand, TNF, IL-1β, and IL-17 levels but increased osteoprotegerin levels. Our data suggest that total flavonoids of B. pilosa attenuate collagen-induced arthritis by suppressing the receptor activator of nuclear factor-κB ligand/receptor activator of nuclear factor-κB/osteoprotegerin pathway and the subsequent production of proinflammatory cytokines. In addition, total flavonoids of B. pilosa may be a promising therapeutic candidate for the management of rheumatoid arthritis.

scholarly journals Circulating Receptor Activator of Nuclear Factor-κB (RANK), RANK ligand (RANKL), and Mammographic Density in Premenopausal Women

2018 ◽  
Vol 11 (12) ◽  
pp. 789-796 ◽  
Author(s):  
Adetunji T. Toriola ◽  
Catherine M. Appleton ◽  
Xiaoyu Zong ◽  
Jingqin Luo ◽  
Katherine Weilbaecher ◽  
...  
Keyword(s):  
Mammographic Density ◽  
Premenopausal Women ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Rank Ligand ◽  
Receptor Activator

scholarly journals Terapia biológica en enfermedades reumatológicas

2013 ◽  
Vol 24 (2) ◽  
pp. 141 ◽  
Author(s):  
Manuel F. Ugarte-Gil ◽  
Eduardo M. Acevedo-Vásquez ◽  
Graciela S. Alarcón
Keyword(s):  
T Lymphocyte ◽  
B Lymphocyte ◽  
Cytotoxic T Lymphocyte ◽  
Nuclear Factor Κb ◽  
Nuclear Factor ◽  
Lymphocyte Antigen ◽  
Receptor Activator ◽  
B Lymphocyte Stimulator

El advenimiento del uso de terapias biológicas en Reumatología ha modificado significativamente el pronóstico de pacientes portadores de artritis reumatoide (AR), artritis juvenil (AJ), espondilitis anquilosante (EA), entre otras enfermedades. A diferencia de las terapias convencionales estos productos biológicos se dirigen a los llamados blancos terapéuticos ya sea estas una línea celular, un mediador inflamatorio o un receptor de superficie. Estos compuestos son producidos por células vivas mediante la tecnología del ADN recombinante. Estos compuestos pueden tener componentes humano y animal [quiméricos (Xi), humanizados (Zu)], o completamente humanos (H) lo cual se reconoce por las letras que se incluyen en el nombre de cada uno. En el campo de la Reumatología, el primer compuesto utilizado fue el etanercept (anti-factor de necrosis tumoral o anti-TNF) aprobado en 1998, pero otros anti-TNF han demostrado su beneficio en AR, como en EA y AJ. Los inhibidores de Interleucina (IL-1) casi no se usan en AR actualmente, pero si los inhibidores de IL-6, así como los agentes contra las células B y los agonistas de CTLA-4 (Cytotoxic T lymphocyte antigen). Existe asimismo un compuesto dirigido al BLyS (B-lymphocyte stimulator) el cual se usa en lupus eritematoso sistémico y otro dirigido al receptor activador del factor nuclear κB (RANKL, receptor activator of nuclear factor-κB ligand) que se usa en osteoporosis. Con el avance en el conocimiento de la patogenia de las enfermedades reumáticas, se vienen reconociendo otra blancos terapéuticas. En los años venideros, este campo ha de expandirse en proporciones geométricas.

Sign in / Sign up

Export Citation Format

Share Document